Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Journal of Clinical Oncology · 10.04.2025 · 43 (11) · 1358-1368
DOI: 10.1200/jco-24-02524 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2025. Verfasst von Breelyn A Wilky und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Cancer Center, Aurora, CO. Hauptthemen laut MEDLINE: Sarcoma, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in advanced sarcomas. METHODS BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years. The primary end point was to determine dose-limiting toxicities during the dose-escalation period. Secondary end points include objective response rate (ORR), duration of response (DOR), disease control rate, and progression-free survival (PFS) by RECIST 1.1. Exploratory end points include assessing patient biomarkers including tumor mutational burden, cytokines, and PD-L1 expression. RESULTS Overall, 64 patients with sarcoma were treated; all were evaluable for safety and 52 for efficacy. The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. No grade 4 or 5 TRAEs were reported. For all evaluable patients, ORR was 19.2% (95% CI, 9.6 to 32.5), and 27.8% (95% CI, 9.7 to 53.5) for evaluable patients with angiosarcoma (n = 18); 33.3% in visceral and 22.2% in cutaneous subtypes. Median PFS for evaluable patients was 4.4 months (95% CI, 2.8 to 6.1), with a 6-month PFS rate of 36% (95% CI, 22 to 50) and a median DOR of 21.7 months (95% CI, 1.9 to not reached). CONCLUSION The combination of BOT/BAL demonstrated promising efficacy and safety in a large cohort of heavily pretreated sarcoma patients. This encouraging activity warrants further investigation (ClinicalTrials.gov identifier: NCT03860272 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Colorado Cancer Center, Aurora, CO.
- Case Comprehensive Cancer Center, Cleveland, OH.
- HonorHealth Research Institute, Scottsdale, AZ.
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
- Beth Israel Deaconess Medical Center, Boston, MA.
- Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine, New York, NY.
ORCID-Profile: Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, Anthony B El-Khoueiry, Andrea J Bullock, Brian Henick, Mark Agulnik, Daruka Mahadevan, Justin Stebbing, Chloe Delepine, Dhan Chand, Manushak Avagyan, Joseph E Grossman, Jonathan C Trent, Robin L Jones, Apostolia M Tsimberidou
Zitieren
APA
Wilky, B. A., Schwartz, G. K., Gordon, M. S., El-Khoueiry, A. B., Bullock, A. J., Henick, B., Agulnik, M., Singh, A., Mahadevan, D., Stebbing, J., Delepine, C., Chand, D., Avagyan, M., Wu, W., Johnson, B., Grossman, J. E., O'Day, S., Trent, J. C., Jones, R. L., & Tsimberidou, A. M. (2025). Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. Journal of Clinical Oncology, 43(11), 1358-1368. https://doi.org/10.1200/jco-24-02524
Vancouver
Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, et al. Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. Journal of Clinical Oncology. 2025;43(11):1358-1368. doi:10.1200/jco-24-02524
BibTeX
@article{Wilky2025,
author = {Wilky, Breelyn A and Schwartz, Gary K and Gordon, Michael S and El-Khoueiry, Anthony B and Bullock, Andrea J and Henick, Brian and Agulnik, Mark and Singh, Arun and Mahadevan, Daruka and Stebbing, Justin and Delepine, Chloe and Chand, Dhan and Avagyan, Manushak and Wu, Wei and Johnson, Benny and Grossman, Joseph E and O'Day, Steven and Trent, Jonathan C and Jones, Robin L and Tsimberidou, Apostolia M},
title = {Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {11},
pages = {1358--1368},
doi = {10.1200/jco-24-02524}
}
EUVIMED